Maximus (MMS) Q4 2025 earnings review
Profitability Shines Despite Revenue Reset; FY26 Guidance Points to Higher Earnings on Lower Sales
Maximus closed FY25 with strong results, delivering 3.9% organic growth and a 20% increase in adjusted EPS for the year. However, the outlook for FY26 points to a revenue reset, with guidance implying a ~2% YoY decline at the midpoint. This is driven by the anticipated loss of non-recurring, high-volume work in clinical and disaster support programs that boosted FY25. Despite the top-line headwind, the core story is one of significant, accelerating profitability. Management is guiding for adjusted EBITDA margins to expand to 13.7% in FY26 (from 12.9% in FY25), which, combined with aggressive share repurchases, is expected to drive a healthy ~10% growth in adjusted EPS. The company is successfully managing a transition year, prioritizing margin expansion and shareholder returns while positioning for long-term growth from technology initiatives and new legislation.
🐂 Bull Case
The margin expansion story is robust and accelerating. Guidance for a 13.7% adjusted EBITDA margin in FY26, up from 12.9% in FY25 and 11.6% in FY24, demonstrates successful execution of technology and cost-control initiatives.
After resolving Q3's collection delays with a massive $642M free cash flow quarter in Q4, the company is guiding for up to $500M in FY26. This financial strength, coupled with low leverage (1.5x), enables significant shareholder returns via buybacks.
While FY26 is a transition year, key future growth drivers remain. These include the expansion into U.S. Federal markets, the deployment of AI-enabled services, and the significant multi-year opportunity from the 'One Big Beautiful Bill Act'.
🐻 Bear Case
FY26 guidance marks a reversal from growth to a decline in revenue. The business is facing a ~3% headwind from losing non-recurring high-volume work from FY25, indicating the core portfolio's near-term growth is muted.
The much-discussed growth catalyst from the 'One Big Beautiful Bill Act' impacting Medicaid and SNAP is primarily an FY27 story. The U.S. Services segment, which stands to benefit, faces another year of potential contraction.
⚖️ Verdict: 🟢
Bullish. While the revenue decline in the FY26 guidance is a clear headwind, the accelerating profitability and robust cash flow are more compelling. Management is effectively navigating a reset year by focusing on higher-margin activities and shareholder returns. The guidance appears prudently de-risked, setting a higher floor for earnings and positioning the company for a return to growth in FY27 from a more profitable base.
Key Themes
Margin Expansion is the Core Story
Maximus is successfully executing a margin improvement strategy. Adjusted EBITDA margin is guided to expand for the third consecutive year to 13.7% in FY26. This is driven by a combination of technology-led productivity gains, a disciplined cost management approach (evidenced by a $16M Q4 severance charge), and a focus on higher-value work. The U.S. Federal Services segment, with a guided margin of 15.5%-16.0%, is a key contributor to this high-quality earnings profile.
Revenue Growth Reverses in FY26 Outlook
A key concern contradicting the long-term growth narrative is the near-term revenue outlook. The midpoint of FY26 guidance ($5.325B) implies a 1.9% YoY decline, a sharp reversal from the 3.9% organic growth in FY25. Management attributes this to a 3% headwind from lapping non-recurring high-volume clinical and disaster support work, indicating the underlying growth of the base business is just 1%.
U.S. Federal Services Remains a High-Quality Engine
The U.S. Federal segment was the primary growth driver in FY25, with revenue up 12.1%. While management expects a mild contraction in FY26 due to the loss of excess volumes, the segment's profitability is set to improve further. The guided operating margin of 15.5%-16.0% (up from 15.3% in FY25) underscores the strength and high-quality earnings contribution of this business.
U.S. Services Segment Continues to Lag
The U.S. Services segment remains a weak spot. Revenue declined 7.7% in FY25 as it lapped the high volumes from the Medicaid unwinding exercise. Management expects another year of 'mild contraction' in FY26. The major legislative catalyst, the 'One Big Beautiful Bill Act', is not expected to materially contribute until FY27, leaving the segment without a clear near-term growth driver.
Robust Cash Generation Enables Shareholder Returns
The company demonstrated strong cash management by resolving the Q3 DSO spike, delivering $642M in free cash flow in Q4. FY26 guidance calls for an even stronger year, with FCF of $450M-$500M. This financial firepower supports the capital allocation strategy, which included $457M in share repurchases in FY25 and provides flexibility for future returns and strategic M&A.
AI & Automation as a Strategic Priority
Management heavily emphasized its evolution into a technology-driven partner. The company has already deployed AI-driven tools to enhance productivity and plans for approximately 30 more AI-related deployments in FY26. These initiatives are not just conceptual; they are a core driver of the guided margin expansion and a key part of the company's long-term strategy to deliver higher-value, tech-enabled services.
Book-to-Bill Remains Below 1.0x
The trailing-twelve-month book-to-bill ratio at year-end was 0.9x. While management attributed this to a period of lower-than-normal rebid activity, a ratio below 1.0x is a traditional indicator of potential future organic growth challenges and warrants monitoring.
Other KPIs
Stable. DSO improved dramatically from a peak of 96 days in Q3 back to 62 days, resolving a key investor concern from the prior quarter. This confirms management's narrative that the Q3 cash flow issue was a temporary collections delay on two large contracts and that working capital management is now back on track.
Improving. The company ended the year with a net leverage ratio of 1.5x, down from 2.1x in Q3 and comfortably below its 2.0x-3.0x target range. This provides significant financial flexibility for capital allocation priorities, including M&A and continued opportunistic share repurchases.
Improving. Following the divestiture of volatile employment services businesses, this segment is showing improved and more stable profitability. The operating margin improved to 3.7% in FY25 from just 1.2% in FY24, and it is guided to remain in a healthy 3% to 5% range for FY26.
Guidance
Reversing. The midpoint of $5.325B implies a 1.9% decline from FY25 revenue of $5.431B. This marks a reversal from the 3.9% organic growth achieved in FY25. The decline is attributed to a ~3% headwind from the roll-off of temporary, high-volume clinical and disaster-related work.
Decelerating. The midpoint of $8.10 represents a strong 10.1% increase over FY25's $7.36. While this is a deceleration from the 20% growth seen in FY25, it is a high-quality result driven by significant margin expansion and a lower share count, which more than offset the forecasted revenue decline.
Accelerating. The midpoint of $475M implies a 30% increase over the $366M generated in FY25. This reflects confidence in continued strong collections and a lower forecast for capital expenditures, underpinning the company's robust capital return potential.
Key Questions
Quantifying FY26 Revenue Headwinds
Your FY26 revenue guidance implies a 3% headwind from non-recurring volumes. Could you break down this impact between the U.S. Federal and U.S. Services segments and provide the underlying 'core' organic growth rate you expect from each?
Path to 'One Big Beautiful Bill Act' Monetization
You've positioned the OBBBA as a major FY27 catalyst. What specific leading indicators, such as state RFIs or RFPs, should investors monitor during FY26 to gain confidence that this opportunity is materializing on schedule?
Sustainability of Margin Expansion
The guided expansion to a 13.7% Adjusted EBITDA margin is impressive. How much of this improvement is driven by permanent technology-led efficiencies versus more temporary cost-cutting measures, and how should we think about margin sustainability if revenue growth accelerates in FY27?
Capital Allocation Priorities
With leverage now at a low 1.5x and a strong free cash flow outlook, how are you prioritizing capital between strategic M&A, particularly in the defense and national security space, and further opportunistic share repurchases?